Skip to main content

Table 2 Adverse effects associated with amikacin

From: Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada

Adverse effects N (%)
Ototoxicity
 Subjective symptoms 43/107 (40.2%)
 Hearing impairment seen in audiograms 30/77 (39.0%)
 Nephrotoxicity 6/96 (6.2%)
 Vestibular toxicity 4/107 (3.7%)
PICC related complications
 Venous thromboembolism 7/107 (6.5%)
 Bloodstream infection 1/107 (0.9%)
 Fatigue 6/107 (5.6%)
 Skin rash 5/107 (4.7%)
 Paresthesias 1/107 (0.9%)
 Restless extremities 1/107 (0.9%)
  1. PICC Peripherally Inserted Central Catheter